What is SHINGRIX?
SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:
- adults 50 years of age or older;
- adults 18 years of age or older at increased risk of HZ.1
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:
SHINGRIX is contraindicated to anyone with hypersensitivity to the active substances or to any of the excipients. Please refer to the prescribing information for further details.
References
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
Date of Preparation: January 2023 PM-IE-SGX-WCNT-220002